Piramal Enterprises Ltd (PEL):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Piramal Enterprises Ltd (PEL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3414
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Piramal Enterprises Ltd (PEL), is a provider of medicines and healthcare finance services. The company offers products such as Critical Care, Consumer Care, BST-CarGel, Phyto Medicines, Anaesthesias, Orthopedic medicines, Halothane, Isoflurane , Sevoflurane and other OTC related medicines. It also offers contract manufacturing and development services, pharma solutions, critical care solutions, imaging services, and other services such as fund management, structured investments and information management services. The company serves life sciences, financial services,health care, health care information management, specialty glass packaging and real estate sectors. It operates over 110 countries, including, India, Sri Lanka, Germany, Italy, the UK, France, Canada, the US and other countries. PEL is headquartered in Mumbai, Maharashtra, India.

Piramal Enterprises Ltd (PEL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Piramal Enterprises Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Piramal Enterprises Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Piramal Enterprises Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Piramal Enterprises Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Piramal Enterprises Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Piramal Enterprises Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Piramal Enterprises Ltd, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Piramal Critical Care Acquires Yargesa from Edenbridge Pharma 14
Piramal Enterprises Acquires Digeplex and Associated Brands from Shreya Life Sciences 15
Piramal Enterprises Acquires Intrathecal Therapy Business from Mallinckrodt for 203 Million 16
Piramal to Acquire Five Anesthesia and Pain Management Injectable Products from Janssen Pharma 18
Piramal Enterprises Plans to Acquire Over The Counter Business from Morepen Labs 19
Piramal Enterprises Acquires Five OTC Brands from Organon India and MSD for USD14 Million 20
Piramal Enterprises Acquires Caladryl Brand From Valeant Pharma 21
Piramal Healthcare Completes Acquisition Of Molecular Imaging Development Portfolio Of Bayer Pharma 22
Private Equity 23
Piramal Enterprises Mulls Sale of Up to 20% Stake in OTC Drugs Business 23
Partnerships 24
Terumo Enters into Distribution Agreement with Piramal Critical Care 24
Cumberland Pharma Enters into Agreement with Piramal Critical Care 25
Piramal Enterprises Forms Joint Venture with Navin Fluorine International 26
Goodwin Biotech Enters Into Co-Development Agreement With Coldstream Labs For Cytotoxic Antibody Drug Conjugates 27
Piramal Enterprises Enters Into Co-Development Agreement With Tata Memorial Centre 28
Fujifilm Diosynth Biotech Enters Into Agreement With Piramal Healthcare To Develop Antibody Drug Conjugates 29
Licensing Agreements 30
Piramal Imaging Enters into Licensing Agreement with Isologic Innovative Radiopharma 30
AC Immune Enters Into License Agreement With Piramal Imaging 31
Presage Biosciences Enters into Licensing Agreement with Piramal Enterprises 33
Equity Offering 34
Piramal Enterprises Plans to Raise Funds through Public Offering 34
Piramal Enterprises Plans to Raise Up to USD774.6 Million in Issue of Securities 35
Debt Offering 36
Piramal Enterprises Raises USD770 Million in Private Placement of Debentures 36
Piramal Enterprises Raises USD51.6 Million in Private Placement of Debentures 37
Piramal Enterprises to Raise USD19.38 Million in Private Placement of Debentures 38
Asset Transactions 39
Indoco Remedies Acquires Clinical Research Division from Piramal Enterprises 39
Acquisition 40
Piramal Enterprises Acquires Ash Stevens 40
Piramal Acquires Coldstream for USD30.6 Million 41
Third Avenue Management Acquires 1.26% Stake In Piramal Enterprises From Morgan Stanley For US$21 Million 42
Piramal Healthcare Plans To Acquire Contract Manufacturing Companies 43
Piramal Healthcare Plans To Acquire Pharma Company In Europe 44
Piramal Enterprises Ltd – Key Competitors 45
Piramal Enterprises Ltd – Key Employees 46
Piramal Enterprises Ltd – Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Recent Developments 50
Strategy And Business Planning 50
Mar 22, 2017: Piramal Pharma Solutions Augments Integrated Capabilities by Expanding Sterile Manufacturing Capabilities in Lexington, KY 50
Financial Announcements 51
Jul 30, 2018: Piramal Enterprises reports consolidated results for the first quarter ended June 30, 2018 51
May 28, 2018: Piramal Enterprises Limited announces Consolidated Results for the Full Year & Fourth Quarter ended 31 Mar 2018 53
Corporate Communications 55
Mar 20, 2017: Piramal Pharma Solutions Names Stuart E. Needleman as Chief Commercial Officer 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List of Tables
Piramal Enterprises Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Piramal Enterprises Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Piramal Enterprises Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Piramal Enterprises Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Piramal Enterprises Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Piramal Enterprises Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Piramal Enterprises Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Piramal Critical Care Acquires Yargesa from Edenbridge Pharma 14
Piramal Enterprises Acquires Digeplex and Associated Brands from Shreya Life Sciences 15
Piramal Enterprises Acquires Intrathecal Therapy Business from Mallinckrodt for 203 Million 16
Piramal to Acquire Five Anesthesia and Pain Management Injectable Products from Janssen Pharma 18
Piramal Enterprises Plans to Acquire Over The Counter Business from Morepen Labs 19
Piramal Enterprises Acquires Five OTC Brands from Organon India and MSD for USD14 Million 20
Piramal Enterprises Acquires Caladryl Brand From Valeant Pharma 21
Piramal Healthcare Completes Acquisition Of Molecular Imaging Development Portfolio Of Bayer Pharma 22
Piramal Enterprises Mulls Sale of Up to 20% Stake in OTC Drugs Business 23
Terumo Enters into Distribution Agreement with Piramal Critical Care 24
Cumberland Pharma Enters into Agreement with Piramal Critical Care 25
Piramal Enterprises Forms Joint Venture with Navin Fluorine International 26
Goodwin Biotech Enters Into Co-Development Agreement With Coldstream Labs For Cytotoxic Antibody Drug Conjugates 27
Piramal Enterprises Enters Into Co-Development Agreement With Tata Memorial Centre 28
Fujifilm Diosynth Biotech Enters Into Agreement With Piramal Healthcare To Develop Antibody Drug Conjugates 29
Piramal Imaging Enters into Licensing Agreement with Isologic Innovative Radiopharma 30
AC Immune Enters Into License Agreement With Piramal Imaging 31
Presage Biosciences Enters into Licensing Agreement with Piramal Enterprises 33
Piramal Enterprises Plans to Raise Funds through Public Offering 34
Piramal Enterprises Plans to Raise Up to USD774.6 Million in Issue of Securities 35
Piramal Enterprises Raises USD770 Million in Private Placement of Debentures 36
Piramal Enterprises Raises USD51.6 Million in Private Placement of Debentures 37
Piramal Enterprises to Raise USD19.38 Million in Private Placement of Debentures 38
Indoco Remedies Acquires Clinical Research Division from Piramal Enterprises 39
Piramal Enterprises Acquires Ash Stevens 40
Piramal Acquires Coldstream for USD30.6 Million 41
Third Avenue Management Acquires 1.26% Stake In Piramal Enterprises From Morgan Stanley For US$21 Million 42
Piramal Healthcare Plans To Acquire Contract Manufacturing Companies 43
Piramal Healthcare Plans To Acquire Pharma Company In Europe 44
Piramal Enterprises Ltd, Key Competitors 45
Piramal Enterprises Ltd, Key Employees 46
Piramal Enterprises Ltd, Other Locations 47
Piramal Enterprises Ltd, Subsidiaries 47

List of Figures
Piramal Enterprises Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Piramal Enterprises Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Piramal Enterprises Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Piramal Enterprises Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Piramal Enterprises Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Piramal Enterprises Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Piramal Enterprises Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Piramal Enterprises Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Piramal Enterprises Ltd, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Piramal Enterprises Ltd (PEL):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Browns Brasserie and Bar:企業の戦略・SWOT・財務情報
    Browns Brasserie and Bar - Strategy, SWOT and Corporate Finance Report Summary Browns Brasserie and Bar - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • AIB Group Plc:企業の戦略・SWOT・財務情報
    AIB Group Plc - Strategy, SWOT and Corporate Finance Report Summary AIB Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Heijmans NV:企業の戦略・SWOT・財務情報
    Heijmans NV - Strategy, SWOT and Corporate Finance Report Summary Heijmans NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • M3 Inc (2413):企業の財務・戦略的SWOT分析
    M3 Inc (2413) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • AA PLC:企業の戦略・SWOT・財務情報
    AA PLC - Strategy, SWOT and Corporate Finance Report Summary AA PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Airest S.p.A.:企業の戦略・SWOT・財務分析
    Airest S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Airest S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • G1 Therapeutics Inc (GTHX):製薬・医療:M&Aディール及び事業提携情報
    Summary G1 Therapeutics Inc (G1 Therapeutics), formerly G Zero Therapeutics Inc, is a clinical stage biopharmaceutical company that discovers, develops and commercializes therapeutics for the treatment of cancer. The company’s pipeline products include trilaciclib (G1T28), a CDK4/6 inhibitor to pres …
  • F. Hoffmann-La Roche Ltd:企業の戦略・SWOT・財務情報
    F. Hoffmann-La Roche Ltd - Strategy, SWOT and Corporate Finance Report Summary F. Hoffmann-La Roche Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • A2A SpA (A2A):企業の財務・戦略的SWOT分析
    A2A SpA (A2A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Mercy:企業の戦略的SWOT分析
    Mercy - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This u …
  • Technology Nexus AB:企業の戦略的SWOT分析
    Technology Nexus AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • GMT Exploration Co LLC:石油・ガス:M&Aディール及び事業提携情報
    Summary GMT Exploration Co LLC (GMT Exploration) is a oil and natural gas company. It is engaged in the generation, operation and development of oil and natural gas properties primarily located in Alaska, East Texas, Montana, New Mexico and Wyoming. The Company’s identifies, acquires and operates re …
  • Xiangxue Pharmaceutical Co Ltd (300147):製薬・医療:M&Aディール及び事業提携情報
    Summary Xiangxue Pharmaceutical Co Ltd (XPH) is a pharmaceutical company that manufactures and distributes drugs and medicines. The company’s products include drugs, Chinese medicine pieces, medical instruments, health products and medicinal drinks, among others. It also provides healthcare suppleme …
  • Eneva SA (ENEV3):石油・ガス:M&Aディール及び事業提携情報
    Summary Eneva SA (Eneva), formerly MPX Energia SA, is an integrated energy company. The company offers power generation, energy commercialization, and exploration and production of hydrocarbons and natural gas. Its power generation portfolio includes fossil fuels such as coal and natural gas, and re …
  • NuVasive Inc (NUVA):企業の財務・戦略的SWOT分析
    NuVasive Inc (NUVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Biosense Webster Inc-医療機器分野:企業M&A・提携分析
    Summary Biosense Webster Inc (Biosense Webster), a subsidiary of Johnson & Johnson is a medical device company that offers cardiac arrhythmias products. The company designs, manufactures and markets products for diagnosis and treatment of cardiac arrhythmias. Its products comprise ablation catheters …
  • China Medical System Holdings Ltd (867):企業の財務・戦略的SWOT分析
    Summary China Medical System Holdings Ltd (CMS) is a pharmaceutical service provider that markets, promotes, and sells prescription drugs to all therapeutic departments in hospitals. The company offers products such as deanxit, ursofalk, augentropfen stulln mono eye-drops, exacin, xinhuosu, salofalk …
  • Nichols plc:戦略・SWOT・企業財務分析
    Nichols plc - Strategy, SWOT and Corporate Finance Report Summary Nichols plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Veolia Environnement SA (VIE):電力:M&Aディール及び事業提携情報
    Summary Veolia Environnement SA (Veolia) is an environmental management services company that designs and offers water, waste and energy management solutions. Its service offerings include wastewater and sanitation services, drinking water treatment and distribution and waste management and energy s …
  • KPIT Technologies Ltd (KPIT):企業の財務・戦略的SWOT分析
    KPIT Technologies Ltd (KPIT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆